In addition, in vivo studies demonstrated that MSC-ABs reduced the level of inflammatory cytokines IL-1β, IL-18, and TNF-α by downregulating the expression of NF-kB p65, C-C motif chemokine 17 (CCL-17) and CCL-24, eventually alleviating trinitrobenzene-sulfonic acid (TNBS)-induced experimental colitis [69,70]. This evidence concerns the gene CCL17 and colitis.